

# Index

- acetyl-coA 300  
 acetylation of histones 45, 50, 63, 124  
   *see also* histone deacetylases  
 acetylsalicylic acid 236  
 acute lymphoblastic leukemia (ALL)  
   chemotherapy 81  
   maintenance gene underexpression  
     26–8  
   miRNAs and epigenetics 122  
   molecular subtypes 504  
 acute myeloid leukemia (AML) 145,  
   418, 444–6, 504  
 acute promyelocytic leukemia (APL)  
   445  
 ADAR proteins 145  
 adjacency matrix 460–1  
 affinity-purification mass-  
   spectrometry (AP-MS) 230–1  
 Affymetrix microarrays 413  
 AFP (alpha-fetoprotein) 488  
 AKT signaling pathway (protein  
   kinase B, PKB) 173, 187, 193–6  
   activating mutations 198  
   and eIF4E binding proteins 75  
   in glioblastoma 326, 329  
   glucose metabolism 196, 297  
   inhibitors 190  
   and mTORC1 78, 196  
   and TGF $\beta$  147  
 aldehyde dehydrogenase (ALDH) 353  
 ALK/ALK (anaplastic lymphoma  
   kinase) 421, 435  
   *ALK-EML4* translocations 427–9,  
   436, 507  
 ALK1-7 (activin-like receptors 1-7)  
   205–6  
 ALL *see* acute lymphoblastic leukemia  
 all-trans retinoic acid (ATRA) 445  
 alpha-catenin 277–8, 393  
 alpha-fetoprotein (AFP) 488  
 alternative lengthening of telomeres  
   (ALT) 171  
 AML (acute myeloid leukemia) 145,  
   418, 444–6, 504  
 anaphase promoting complex/  
   cyclosome (APC/C) 37, 42  
 androgen deprivation therapy 361,  
   366–7  
 aneuploidy 100, 102–5, 391  
 angiogenesis 313–15  
   AKT 196  
   CA 15-3 overexpression 487  
   HIF-1 $\alpha$  78–9, 171, 314  
   in metastasis 284, 310  
   miRNA regulators 140, 143  
   p53 171  
   in stomach cancer 396  
   TAMs 285  
   therapeutic targets 290, 316, 327  
   VEGF 171, 196, 284, 288, 314  
*ANGPTL4/ANGPTL4* (angiopoietin-  
   like 4) 289, 354  
 animal models of cancer 169  
 anoikis 282, 285–6, 299  
   resistance 363  
 anti-adhesive therapeutics 317  
 anticoagulants 316–17  
 antioxidants  
   in the cell 298–9, 301  
   dietary 158–60  
 antisense oligonucleotides  
   targeting apoptosis 266  
   targeting eIF4E 82  
   targeting RAS 189  
   targeting TGF $\beta$  213  
 Apaf-1 protein 261, 285–6  
 APC (adenomatous polyposis coli)  
   226, 245, 377, 379  
   stomach cancer 391, 396  
 APC/C (anaphase promoting  
   complex/cyclosome) 37, 42  
 APL (acute promyelocytic leukemia)  
   445  
 apoptosis 256–67  
   in cancer 264–5, 395–6  
   blocked origin licensing 49  
   c-Myc 450–1  
   and EMT 363  
   extrinsic pathway 259, 262–4  
   in cancer 265, 396  
   therapeutic targets 266–7  
   intrinsic pathway 259–64, 285–6  
   in cancer 264–5  
   therapeutic targets 266  
   metastasis and 282, 285–6, 288, 299  
   miRNAs targeting BCL2 139  
   proteins involved in pathways 256  
   AKT 195–6  
   Bcl-2 256–7, 259–61, 263–4, 266  
   caspases 257–8, 261–2, 288  
   DD superfamily 258–9, 262, 265  
   eIF4E 74–5  
   endonucleases 259  
   FoxO 195–6, 264  
   IAPs 259, 262–3, 266  
   NF- $\kappa$ B 263–4  
   p53 172, 263, 450–1, 480  
   RAS proteins 286  
   TGF $\beta$  208  
   regulation 261–2  
   transcription factors 263–4  
   as a therapeutic target 265–7  
 aquaporins 334  
 ARF/Arf (p14, *CDKN2A*) 172, 330–1,  
   412, 450 *see also* p16<sup>INK4A</sup>  
   (*CDKN2A*)  
 Argonaute proteins (AGO) 136–7  
 ARID1A (tumor suppressor) 430  
 arsenic 161  
 astrocytoma *see* glioblastoma  
   multiforme  
 ATM (ataxia-telangiectasia-mutated)  
   427, 481–2  
   ATM/Chk2 pathway 42–5  
 ATP, regulation of glycolysis 302  
   *see also* energy metabolism  
 ATP-dependent citrate lyase (ACL)  
   300  
 ATR (ataxia-telangiectasia mutated  
   and rad3-related) 42–4, 449  
 ATRA (all-trans retinoic acid) 445  
 AURKA (Aurora kinase A) 160  
 AXIN/Axin 226, 245  
 5-aza-2'-deoxycytosine (5-AZA) 115,  
   145  
 B cell malignancies  
   CLL 451–2  
   DLBCL 447–50, 504  
   multiple myeloma 76, 446–7, 504  
 B cell receptor (BCR) 95, 451–2  
 BAD/Bad (Bcl-2 protein) 187, 195,  
   261, 265  
 Bak (Bcl-2 protein) 261  
 Barrett's esophagus 108, 460  
 basement membrane, and metastasis  
   284–5, 316–17

- BAX/Bax (Bcl-2 protein) 261, 265, 380, 393, 396
- BBD peptide inhibitor (BPI) 449–50
- BCL-2/Bcl-2 protein family 256–7
- apoptosis 256–7, 259–61, 263–4, 266
- in cancer 264–5, 380
- lymphoma 450
- stomach 393, 396
- and chemoresistance 325
- regulation 261, 263–4
- AKT 187, 195
- miRNA 139
- as a therapeutic target 266
- BCL-6/Bcl-6 122, 448–50
- BCL-10 448
- BCR (B cell receptor) 95, 451–2
- benign prostate hyperplasia (BPH) 361
- $\beta$ -catenin (and Wnt pathway) 223–4, 367
- and IGF/E-cadherin 370
- and TCF7L2 174, 229
- computer models 245–6
- in cancer 226–7
- APC mutations in GI cancers 226, 245, 379, 396
- prostate 367–8
- proteomics 231–2
- RNAi 228–9
- target genes 233–5
- bevacizumab (Avastin®) 290, 327
- Bid (Bcl-2 protein) 260–1, 263
- Bim (Bcl-2 protein) 260–1, 264, 450
- bioinformatics
- biomarker discovery 469–71
- biomarker validation 467–8
- in genomics
- housekeeping genes in cancer 25–31
- pancreatic cancer 415–16
- sequencing analysis 13–15
- tissue-specific genes in cancer 22
- in metabolomics 304
- in pharmacogenomics 501–3, 511–12
- network biology/medicine 460–3, 502–3
- omics data analysis 240–4
- transcriptional networks 58
- Wnt pathway simulation 244–6
- biomarkers
- categories 458
- screening 458–60, 465, 470
- systems biology approach to research 464–71
- validation 458, 467–8
- see also* prognosis, biomarkers; therapeutic response markers
- bisphenol A 161
- bisphosphonates 290
- black ethnicity (in breast cancer) 345
- BLIMP-1 (B lymphocyte-inducing maturation protein 1) 449–50
- blood group (in stomach cancer) 388
- blood system *see* hematological cancers; vascular system
- Bmi1 (polycomb repressor complex protein) 124
- bone metastasis 287–90, 354, 368
- as a therapeutic target 290
- bone morphogenetic protein (BMP) signaling pathway 206–7, 368–9
- bortezomib (Velcade®) 76, 267, 447
- Boveri, Theodor 93
- BPI (BBD peptide inhibitor) 449–50
- BRAF/BRAF (RAS effector) 188, 190, 379, 478–9
- brain tumors
- metastasis from breast 289
- MRI imaging 490
- tissue-specific genes 23–4
- see also* glioblastoma multiforme
- BRCA1/BRCA2
- in breast cancer 98–100, 346, 351, 355, 481
- in pancreatic cancer 412
- breast cancer 345–56
- BRCA1/BRCA2 98–100, 346, 351, 355, 481
- cancer stem cells 353–5
- cell of origin effects 24, 350–2
- chromosomal abnormalities/CNVs 101–3, 348–9
- classification and grading systems 346–8, 503–4
- epidemiology 345–6, 481
- ER/PR status 24, 185, 346
- genomic studies identifying mutations 4, 348–50
- HER2 amplification 95–6, 199, 346, 355
- heterogeneity 352–3
- IKBKE 177
- metastasis
- differences from primary tumor 349
- gene profiles 353
- miRNAs 142–3
- to specific organs 289, 312, 354–5
- p53 66, 481
- PI3K pathway 199, 479
- prognosis 347–8, 461, 479, 481, 484, 503
- RAS signaling 185
- TGF $\beta$  signaling 212, 353
- treatment
- chemoresistance 353, 355, 510
- endocrine therapies 175, 346
- therapeutic targets 355
- trastuzumab 199, 346, 355, 506
- triple-negative 346–7, 510
- bronchoalveolar stem cells (BASC) 422
- BTG2 (BTG family, member 2) 25
- Burkitt's lymphoma 450–1
- c-FLIP<sub>S</sub> (caspase inhibitor) 81, 262
- CA 15-3 487
- CA 19-9 487
- CA-125 486
- cadherins 283, 285
- and IGF-1 370
- mesenchymal to epithelial transition 287
- in prostate cancer 364
- in stomach cancer 389, 393–4
- calcitonin 368
- calcium signaling
- and RAS 185–7
- Wnt/Ca<sup>2+</sup> 224
- Cancer Genome Atlas (TCGA) 4, 177, 501
- Cancer Genome Project (CGP) 427, 501
- cancer outlier profile analysis (COPA) 502
- cancer stem cell hypothesis 352–3
- cancer stem cells 210, 237–9, 286–7, 354
- in breast cancer 353–5
- Cancer Translation Project 510–11
- carcinoembryonic antigen (CEA) 486–7
- carcinoma of unknown primary 20–2
- CARD proteins (caspase recruitment domains) 257–9
- CARMA1 (CARD11) signalosome
- DLBCL 447–8
- MALT lymphoma 448
- casein kinase 1 (CK1) 223
- caspases 257–8
- in cancer 81, 265
- function 261–2
- regulation 196, 261–2, 288
- CARD proteins 258–9
- c-FLIP<sub>S</sub> 81, 262
- catenin *see* alpha-catenin;  $\beta$ -catenin
- cathepsins 284, 285
- CD4+/CD8+ T cells 208–9, 212, 477
- CD40 447
- CD44 (metastasis suppressor) 143
- CD44<sup>+</sup>/CD24<sup>-</sup> cancer stem cells 210, 286–7, 353–4
- CD133<sup>+</sup> stem cells in glioblastoma 334–5
- CDC6 (cell division cycle 6) 36–7, 39
- Cdc6 defects in yeast inhibit origin licensing 47

## Index

- CDH1 *see* E-cadherin  
 CDH2 (N-cadherin) 364  
 CDK1 (cyclin-dependent kinase 1) 39, 237  
 CDK2 (cyclin-dependent kinase 2) 37–9, 48  
 CDK4 (cyclin-dependent kinase 4) 37, 48, 186, 208  
   *CDK4* amplification in glioblastoma 331  
 CDK6 (cyclin-dependent kinase 6) 37, 122, 186  
 CDK8 (cyclin-dependent kinase 8) 177  
 CDKN1A (cyclin-dependent kinase inhibitor p21) 171  
 CDKN2A (cyclin-dependent kinase inhibitor, *p14<sup>ARF</sup>* or *p16<sup>INK4A</sup>*) 172, 330–1, 429  
   in Burkitt's lymphoma 450  
   in esophageal carcinoma 395  
   in pancreatic cancer 410, 412  
 CDKN2B (cyclin-dependent kinase inhibitor, *p15<sup>INK4B</sup>*) 208, 332  
 cDNA libraries 56–7, 175  
 CDT1 (Cdc10-dependent transcript 1) 36  
   and geminin 40  
   degradation 39–42  
   overexpression 40–1  
 CDT2 39–42  
 CEA (carcinoembryonic antigen) 486–7  
 celecoxib 236, 459  
 cell cycle 36, 106  
   checkpoints 42–5, 171  
   origin licensing 35–40  
   sources of genome instability 104–8  
   deregulation of origin licensing 40–6  
   insufficient origin licensing 46–50  
   TGF $\beta$  signaling 207–8  
 cell lines  
   problems with nomenclature 511  
   used in preclinical studies 507–10  
 centrosomes 108  
 cetuximab (Erbix<sup>®</sup>) 190, 478, 506  
 CGH (comparative genomic hybridization) 96–7, 413  
 CGP (Cancer Genome Project) 427, 501  
 chemokine receptor CXCR4 277, 289, 483–4  
 chemokines 276–8, 289  
 chemoresistance *see* drug resistance  
 chemosensitivity (predictive) markers 458  
   *see also* therapeutic response markers  
 chemotherapy targets *see* drug targets
- ChIP (chromatin immunoprecipitation) technologies 57–8, 115  
 Wnt signaling targets 243  
 chromatin  
   nucleosome free regions 61–2  
   *see also* DNA methylation; histone modification  
 chromatography 303  
 chromosomes  
   cytogenetic analysis 95–7  
   structural alterations 14, 100–1, 104–8  
   aneuploidy 100, 102–5, 391  
   chromosomal instability (CIN) 101–3  
   in breast cancer 101–3, 199, 346, 348–9  
   in colorectal cancer 101–2, 381  
   in glioblastoma 323–4, 330–1  
   in leukemias 139, 451  
   in lung cancer 427–9  
   in pancreatic cancer 410–14  
   in stomach cancer 391–2  
   translocations *see* translocations  
 chronic lymphocytic leukemia (CLL) 451–2  
 chronic myelogenous leukemia (CML) 95  
 CIDE endonucleases 257, 259  
 cilengitide 290  
 cimetidine 317  
 cisplatin 81, 325, 482  
 citric acid cycle (TCA cycle) 299–301  
 classification of cancers  
   breast 346–8, 503  
   by molecular subtype 503–5  
   lung 431  
   stomach 387  
   *see also* staging of cancers  
 CLDN2 (claudin 2) 289  
 clinical trials  
   in personalized medicine 458–9, 506–7  
 CLL (chronic lymphocytic leukemia) 451–2  
 clock genes 162  
 clonal amplification 9  
 clonal evolution model 109, 352–3  
 clustering analysis 240  
 CML (chronic myelogenous leukemia) 95  
 CNVs *see* copy number variations  
 coagulation 311, 313, 316–17  
 colon cancer 377–83  
   *APC* mutations and  $\beta$ -catenin 226, 245, 379  
   *CDK8* amplification 177
- CT imaging 489  
 environmental risk factors 377  
 epigenetics 381  
 familial forms  
   FAP 226, 236, 377, 391  
   HNPCC 102, 377–8  
 genome instability 101–2, 380–1  
 genomic studies 381–2  
 metabolomics 382  
 metastasis 312  
 p53 pathway 380  
 PI3K/PTEN pathway 379–80  
 prognosis 482–3, 486–7  
 proteomics 382  
 RAS pathway 188, 379  
 screening 378  
 staging 378  
 TGF $\beta$  pathway 210–12, 380  
 transcriptomics 382  
 treatment 236, 378, 506  
 colonization 282, 287–9  
 colony stimulating factor-1 (CSF-1) 284–5  
 comparative genomic hybridization (CGH) 96–7, 413  
 computed tomography (CT) 489–90  
 copy number variations (CNVs) 14, 426  
   analytical tools 96–7  
   in breast cancer 101–3, 348–9, 510  
   HER-2 amplification 199, 346  
   in glioblastoma 323–4, 331  
   in lung cancer 427  
   in pancreatic cancer 413–14  
   in stomach cancer 391–2  
 COX2/COX2 (cyclooxygenase-2) 171, 277, 396  
   inhibitors (celecoxib) 236, 459  
   crizotinib (Xalkori<sup>®</sup>) 435, 507  
 CRL1<sup>SKP2</sup> (SCF<sup>SKP2</sup>) 39, 41  
 CRL4<sup>CDT2</sup> (ubiquitin E3 ligase) 39–41  
 CSF1 (colony stimulating factor-1) 284, 285  
 CT (computed tomography) 489–90  
 CTNNB1 226  
   *see also*  $\beta$ -catenin  
 curcumin 160  
 CXCR4 (chemokine receptor 4) 277, 289, 483–4  
 cyclin D1 80, 186  
   inhibition 237  
 cyclin D2 25  
 cyclin-dependent kinase inhibitors  
   *see* *CDKN1A*; *CDKN2A*; *CDKN2B*  
 cyclin-dependent kinases *see* *CDK1*; *CDK2*; *CDK4*; *CDK6*; *CDK8*  
 cyclin E 37

- cyclooxygenase-2 (COX2) 171, 277, 396  
 inhibitors (celecoxib) 236, 459  
 cyclopamine 366, 398  
 CYLD (cyclindromatosis protein) 447  
 cytochrome c 261, 285–6  
 cytokines  
 and organ-specific metastasis 289  
 assessment of response to using  
 phosphoflow cytometry 446  
 inflammatory 275–7  
*see also individual cytokines*
- DARP32 396  
 dasatinib 510  
 data analysis  
 biomarker discovery 469–70  
 computer models of Wnt signaling  
 pathways 244–6  
 DNA sequencing 13–15  
 in metabolomics 304  
 in pancreatic cancer genomics  
 415–16  
 in pharmacogenomics 500–3,  
 511–12  
 omics data in general 240–4  
 databases  
 apoptosis-related genes 256  
 cancer-related 4, 415, 469, 501–2  
 genes (in general) 240–1  
 PPI 242  
 signaling pathways (SPEED) 243  
 DCP (des- $\gamma$ -carboxy prothrombin)  
 483  
 DD (death domain) superfamily  
 257–9, 262  
 as a therapeutic target 266–7  
 in cancer 265, 396  
 DED proteins (death effector  
 domains) 257, 259  
 dedifferentiation 20  
*see also epithelial to mesenchymal  
 transition (EMT)*
- deletions  
 in glioblastoma 323–4, 330–1  
 in leukemia 139, 451  
 in lung cancer 427  
 in pancreatic cancer 410–12  
 in stomach cancer 392  
 of miRNAs 139, 141  
 denosumab 290  
 dependence network modelling 469  
 des- $\gamma$ -carboxy prothrombin (DCP)  
 483  
 DHS (DNase I hypersensitivity site) 61  
 diagnosis  
 biomarkers 458  
 early detection 457  
 problems of over- and  
 underdiagnosis 459–60, 465  
 socioeconomic factors working  
 against research 459  
 systems biology approach to  
 research 464–71  
 threshold adjustment in  
 screening programs 470  
 Dicer (RNase III) 136–7  
 diet *see* nutrition  
 differential display PCR (DDRT-PCR)  
 232–3  
 diffuse large B cell lymphoma  
 (DLBCL) 447–50, 504  
 diffusion 246  
 digital karyotyping 96–7  
 DISC (death-inducing signaling  
 complex) 262  
 Dishevelled (Dvl, Dsh) 224–5  
*Dkk1/DKK1* (Dickkopf) 234  
 DLBCL (diffuse large B cell  
 lymphoma) 447–50, 504  
 DNA double-strand breaks (DSB)  
 42–3, 105, 171  
 DNA endonucleases (CIDE family)  
 257, 259  
 DNA fiber assays 46  
 DNA libraries 7–9, 56–7, 175  
 DNA methylation  
 analytical techniques 113–15  
 and diet 156–60  
 developmental impact 162–3  
 and miRNAs 120–2, 144  
 as a therapeutic target 145, 437  
 feedback effects 160–1  
 in cancer 381  
 hypermethylation 119–23, 144,  
 392, 395, 429  
 hypomethylation 119  
 primary site in metastatic  
 cancer 22  
 in ESCs 119  
 in normal cells 117–19  
 molecular mechanisms 116–17,  
 156–9  
 DNA methyltransferases (DNMTs)  
 116–17, 125, 143–4  
 and diet 158–60  
 and TGF $\beta$ /Smad2 210  
 regulation by miRNAs 144  
 DNA repair 124, 171, 197, 484  
 DNA replication  
 nucleotide synthesis 298, 301, 482–3  
 origin firing 36–8  
 origin licensing 35–40  
 deregulation (leading to re-  
 replication) 40–6  
 insufficient 46–50  
 DNA sequencing methods 7–12, 57,  
 96, 126, 233  
 data analysis 13–15  
 DNase I hypersensitivity site (DHS) 61  
 DNMTs *see* DNA methyltransferases  
 double-strand breaks (DSB) 42–3, 105,  
 171  
*DPC4/SMAD4/Smad4*  
 in pancreatic cancer 210–12,  
 410–12  
 in stomach cancer 391, 396  
 DR4/DR5 (death receptors, TRAIL-R1  
 and TRAIL-R2) 262, 267, 396  
 drinking water, contaminated 161  
 driver genes/mutations 3, 15, 95–100,  
 426  
 Drosha (RNase III) 135–6  
*Drosophila melanogaster*  
 apoptosis 256  
 tracheal system development 424  
 Wnt (*wg*) signaling 222, 244–5  
 drug resistance  
 identification of genes 175  
 in breast cancer 353, 355, 510  
 in cells undergoing EMT 365, 437  
 in glioblastoma 325–6, 333  
 in lung cancer 81, 436–7  
 in stomach cancer 398  
 MYC amplification 479  
 to cisplatin 81, 325, 482  
 to EGFR inhibitors 436–7, 478–9,  
 506  
 drug responses *see* therapeutic  
 response markers  
 drug targets *see* therapeutic targets  
 DSB (double-strand breaks) 42–3, 105,  
 171  
 Dsh (Dishevelled) 224–5  
 dsRNA therapies 326  
*DUSP1/DUSP2* (dual specificity  
 phosphatase 1/2) 25, 28  
 E-cadherin 283, 285  
 and IGF-1 370  
 in prostate cancer 364  
 in stomach cancer 389, 393–4  
 mesenchymal to epithelial  
 transition 287  
 E2F/E2F (transcription factor) 140–1,  
 172  
 Early Detection Research Network  
 (NCI) 468  
 ECM (extracellular matrix) 284–5,  
 288, 299, 316–17  
*see also stroma*  
 economic factors in research 459  
 EGFR *see* epidermal growth factor  
 receptor  
 eIF2 (initiation factor 2) 70–1, 75–6,  
 78  
 eIF2B 70, 76  
 eIF3 (initiation factor 3) 76

## Index

- eIF4 (initiation factor 4)  
 as a therapeutic target 28  
 eIF4A 76–7, 80  
 eIF4B 77, 80  
 eIF4E 70–5, 79–80, 82  
 eIF4G 77  
 eIF4E binding proteins (4E-BPs) 71,  
 74–5, 78–9  
 eIF6 (initiation factor 6) 77  
 electron microscopy 12  
 embryonic development  
 EMT 362–3  
 long-term epigenetic effects 162–3  
 lung 423–4  
 prostate gland 361  
 TGF $\beta$  signaling 207  
 Wnt signaling 222  
 embryonic stem cells (ESCs) 119  
 EML4-ALK translocations 427–9, 436,  
 507  
 EMT *see* epithelial to mesenchymal  
 transition  
 emulsion PCR 8  
 ENCODE project 59  
 endothelial cells  
 extravasation of tumor cells 287,  
 289, 311, 315  
 intravasation of tumor cells  
 284  
 endothelial progenitor cells (EPCs)  
 288  
 energy metabolism 296–9, 302  
 glutamine 300–1  
 mitochondrial 299–300  
 enhancer element locator (ELL) 58  
 enrichment analysis 240–1, 502  
 environmental influences  
 colon cancer 377  
 epigenetic modifications 119,  
 155–64  
 lung cancer 421, 425  
 stomach cancer 386–8  
*see also* nutrition  
 epidemiology  
 breast cancer 345–6, 481  
 cancer (in general) 457  
 colon cancer 377–8  
 lung cancer 421, 425  
 stomach cancer 386–8  
 epidermal growth factor receptor  
 (EGFR) 369–70, 432, 484  
 and RAS 184, 189–90  
 as a prognostic marker 484  
 as a therapeutic target 190, 267, 326  
 in lung cancer 435, 484, 505–6  
 personalized medicine 505–7  
 positive indicators 326, 484  
 resistance to inhibitors 436–7,  
 478–9, 506  
 in glioblastoma 324–8  
 in lung cancer 421, 426–8, 432, 437  
 treatment with EGFR inhibitors  
 435, 484, 505–6  
 in pancreatic cancer 411–12  
 in prostate cancer 370  
 in stomach cancer 395  
 inflammation and 277  
 on endothelial cells in tumors 315  
 epigenetics 113–27, 134  
 analytical techniques 113–16, 126  
 and cancer 124, 429–30  
 DNA methylation *see* DNA  
 methylation, in cancer  
 histone modification 124, 429–30  
 and control of origin licensing 45,  
 50  
 and drug resistance 437  
 and embryonic origin of adult  
 diseases 162–3  
 and environmental influences 119,  
 155–64  
 and oxidative stress 160  
 imprinting 119, 429  
 in normal cells 117–19  
 intergenerational effects 161–3  
 international collaborations 124–5  
 miRNA *see* microRNA (miRNA)  
 molecular mechanisms 116–17,  
 156–9  
 transcriptional regulation 58, 61–3,  
 66  
 epithelial to mesenchymal transition  
 (EMT) 283–4, 354, 362–3, 434,  
 477  
 and drug resistance 365, 437  
 cadherins 364  
 experimental models 363–4  
 FGFRs/EGFRs 363–4, 369  
 Hedgehog signaling 366–7  
 IGF 370  
 in prostate cancer 363–70  
 TGF $\beta$  210, 365, 368–9  
 transcription factors 142, 363–6  
 Wnt signaling 367–8  
 ErbB1 *see* epidermal growth factor  
 receptor (EGFR)  
 ERBB2/ErbB2 (HER2/NEU) 484–5  
 and RAS 185, 189  
 as a prognostic marker 485, 506  
 as a therapeutic target 190, 199, 346,  
 355, 506  
 in breast cancer 95–6, 199, 346,  
 355  
 in stomach cancer 395  
 ERBB3 (HER3) 485  
 ERBB4 (HER4) 485  
 ERCC1 (excisional nuclease) 482  
 ERG (transcription factor) 367, 469–70  
 ERK signaling pathway 75, 173, 186,  
 433  
 inhibitors 190  
 erlotinib (Tarceva®) 190, 326, 411–12,  
 435–7, 478  
 ESCs (embryonic stem cells) 119  
 esophageal cancer 108, 395, 460  
 estrogen receptor (ER) status in breast  
 cancer 24, 185, 346  
 etaracizumab 290  
 ethnicity (in breast cancer) 345  
 etoposide 291  
 ETS2 (transcription factor) 197  
 exome sequencing 16–17, 426  
 extracellular matrix (ECM) 284–5,  
 288, 299, 316–17  
*see also* stroma  
 extravasation 282, 285–7, 289, 311,  
 315–16  
 EZH2 (enhancer of zeste homolog 2)  
 144, 430  
 FAM123B protein (WTX) 231  
 familial adenomatous polyposis (FAP)  
 226, 236, 377, 391  
 farnesyltransferase inhibitors 189  
 Fas (death receptor) 262, 265  
 FDG-PET imaging (<sup>18</sup>F-fluoro-2-  
 deoxy-D-glucose) 490–1  
 FHIT (tumor suppressor) 394  
 fibroblast growth factor receptor  
 (FGFR)  
 in prostate cancer 363–4, 369  
 in the lung 424, 429  
 fibronectin receptors 316  
 FISH (fluorescence *in situ*  
 hybridization) 95–6  
 Fisher, Ronald A. 460  
 Fisher's Exact Test 241  
 Flemming, Walther 93  
 flow cytometry 46, 446  
 FLT-PET imaging (3'-deoxy-3'-<sup>18</sup>F-  
 fluorothymidine) 491  
 FLT3 mutations 444–6  
 fluorescence *in situ* hybridization  
 (FISH) 95–6  
 flux balance analysis 304  
 folate 155–6  
 FOXO/FoxO (forkhead) transcription  
 factors 195–6, 264  
 fructose-1,6-bisphosphate (FBP)  
 298  
 fumarate hydratase (FH) 299–300  
 GAPs (GTPase-activating proteins)  
 183, 186, 188, 333–4, 432  
 gas chromatography 303  
 gastric cancer *see* stomach cancer  
 GATA6 (transcription factor) 415

- gatekeeper genes 2–3  
 GBM *see* glioblastoma multiforme  
 gefitinib (Iressa®) 190, 426, 478, 505–6  
 GEFs (guanine nucleotide exchange factors) 184–6, 432–3  
 geminin 40–2, 49  
 gene expression profiling 20–31  
   cDNA microarray analysis 56–7, 175  
   maintenance genes  
     always expressed in tumors 28–31  
     underexpressed in tumors 25–8  
   tissue-specific genes 22  
     brain tumors 23–4  
     breast cancer 24, 347–8, 351  
     colon cancer 382  
     identification of tissue of origin in metastatic cancer 20–2  
     liver cancer 22–3  
     lung cancer 24  
     pancreatic cancer 414  
 gene fusion 100–1  
   ERG/ETV1/TMPRSS2 in prostate cancer 367, 469–70  
   *see also* translocations  
 gene looping 65  
 Gene Ontology (GO) database 241  
 Gene Set Enrichment Analysis (GSEA) 241, 502  
 gene silencing 64–5  
   DNA methylation/  
     hypermethylation 117, 119–20, 429  
   and diet 160  
   histone modification 124  
   in colon cancer 381  
   in stomach cancer 395  
   RNAi 174–5, 228  
   *see also* microRNA (miRNA)  
 gene therapy 82  
 genetic counseling 389  
 genome instability 35  
   and oncogenesis 108–9  
   causes 101–8  
     DNA hypomethylation 119  
     DNA repair malfunction 124, 197  
     origin licensing deregulation 40–6  
     origin licensing insufficiency 46–50  
   chromosome-level changes 14, 100–8, 426  
   early discoveries 93  
   in colon cancer 101–2, 380–1  
   in glioblastoma 323–4  
   in lung cancer 427–9  
   in pancreatic cancer 413–14  
   in stomach cancer 391–3  
   somatic mutations in cancer genomes 14–15, 93–100, 426  
 genome sequencing 7–18  
   analysis 13–15  
   cancer genomes 14–17, 96, 412–18  
   DNA sequencing methods 7–12, 57, 96, 126, 233  
 genome-wide association studies (GWAS) 13  
 geranylgeranyl transferase inhibitors (GGTIs) 189  
 GINS complex 37–8  
 Gleevec® (imatinib, Glivec®) 82, 236, 478  
 glioblastoma multiforme (GBM) 23–4, 323–36  
   aquaporins 334  
   CD133+ stem cells 334–5  
   chromosomal abnormalities 323–4, 330–1  
   classification/subtypes 504–5  
   EGFR 324–8  
   IDH1/IDH2 334  
   MGMT 332–3  
   MSH6 333  
   NF1 333–4  
   p53 pathway 327, 330–1  
   pathway interconnections 326–8, 330, 332–4  
   PDGF 327  
   PI3K pathway 81, 325, 328–9  
     AKT 326, 329  
     PTEN 326, 328–9, 333–4  
   primary and secondary 323–4, 328–30  
   prognosis 331  
   RB1 331–2  
   STAT 329  
   TGFβ 327  
   treatment  
     drug resistance 325–6, 333  
     targets 326–9, 335–6  
     VEGF 326–7  
 glioma stem cells 334–5  
 glucose metabolism 296–9, 302  
   and AKT 196, 297  
   mitochondrial metabolism 299–300  
 glucose transporters (GLUTs) 196, 297  
 glutaminase (GLS1/GLS2) 301  
 glutamine 300–1  
 glycans  
   as therapeutic targets 317  
   synthesis 466–7  
 glyceraldehyde-3-phosphate dehydrogenase 297, 299  
 glycine 298  
 glycogen synthase kinase-3β (GSK-3β) 223, 226, 367  
 glycolysis 296–9, 302  
 glycosylation 262, 301, 466–7  
 Google Flu Trends 512  
 grade of tumors 475–6  
 GTPase-activating proteins (GAPs) 183, 186, 188, 333–4, 432  
 GTPases *see* RAS signaling pathways  
 guanine nucleotide exchange factors (GEFs) 184–6, 432–3  
 GWAS (genome-wide association studies) 13  
 HATs (histone acetyltransferases) 45, 125  
 HCC *see* hepatocellular carcinoma  
 HCG (human chorionic gonadotropin) 488  
 HDACs *see* histone deacetylases  
 Hedgehog (Hh) signaling pathway 366–7, 396–7  
*Helicobacter pylori* 387–8, 395  
 hematological cancers 443–52, 504  
   ALL 26–8, 81, 122  
   AML 145, 418, 444–6, 504  
   Bmi1 overexpression 124  
   CLL 451–2  
   CML 95  
   deletions 139, 451  
   DNA methylation profiles 120  
   eIF4E 80  
   miRNAs 122, 139–40, 451  
   multiple myeloma 76, 446–7, 504  
   NF-κB signaling 446–8  
   therapeutic targets 81–2, 447, 449–50, 452  
   translocations 100  
     CARMA1 components 448  
     in AML/APL 145, 444–5  
     in CML 95  
     MLL locus 445–6  
 heparin 317  
 hepatocellular carcinoma (HCC)  
   IL-6 and 276  
   prognostic markers 483–4, 488  
   tissue-specific genes 22–3  
   transcriptional regulation 67  
   treatment 239  
 hepatocyte growth factor (HGF) 394–5  
 HER1 *see* epidermal growth factor receptor  
 HER2 (human epidermal growth factor receptor 2, ERBB2) 484–5  
   as a prognostic marker 485, 506  
   as a therapeutic target 190, 199, 346, 355, 506  
   in breast cancer 95–6, 199, 346, 355  
   in stomach cancer 395  
 HER3 (ERBB3) 485  
 HER4 (ERBB4) 485

## Index

- Herceptin® (trastuzumab) 190, 199, 346, 355, 506  
 hereditary diffuse gastric cancer (HDGC) 389  
 hereditary non-polyposis colorectal cancer (HNPCC) 102, 377–8  
   stomach cancer 389–90  
 hexokinase 297  
 hexosamines 301  
 HGF (hepatocyte growth factor) 394–5  
 HIF-1/HIF-1 $\alpha$  (hypoxia inducing factor-1)  
   angiogenesis 78–9, 171, 314  
   glucose metabolism 297, 299–300  
   inflammation 277  
 histone acetylation 45, 50, 63, 124  
 histone acetyltransferases (HATs) 45, 125  
 histone deacetylases (HDACs) 125, 430  
   and DNA methylation 117  
   HDAC4 and miR-1 144  
   inhibitors 145, 159, 437  
 histone methylation 62–3, 119, 124  
   and dietary compounds 159–60  
   “bivalent” state in ESCs 119  
 histone methyltransferases (HMTs) 117, 125, 144, 430  
 histone modification  
   analytical techniques 115–16  
   and dietary components 159–60  
   and DNA methylation 117  
   control of DNA replication 45, 50  
   control of transcription 58, 62–3, 66, 119, 124  
   in cancer 124, 429–30  
   in normal cells 117, 119  
   phosphorylation of H2AX 449  
   regulation by miRNAs 144  
 HLA genotype  
   *HLA-DRB4* in leukemia 27–8  
   in stomach cancer 388, 392  
 hnRNP family (heterogeneous nuclear ribonucleoprotein) 298  
 homocysteine 157  
 homopolymer repeats 11  
 HOX (homeobox) genes/proteins 143, 446  
 HPLC (high-performance liquid chromatography) 303  
 HRAS/HRAS 173, 183–4 *see also* RAS signaling pathways  
 human chorionic gonadotropin (hCG) 488  
 Human Genome Project (HGP) 7  
 2-hydroxyglutarate (2-HG) 300  
 hypoxia (in tumors)  
   eIF4E binding proteins 74, 78–9  
   eIF4G 77  
   eIF6 77  
 INK4A *see* *p16<sup>INK4A</sup>* (*CDKN2A*)  
 INK4B (*p15<sup>INK4B</sup>*, *CDKN2B*) 208, 332  
 INK4C (*p18<sup>INK4C</sup>*) 332  
 insulin 196  
 insulin-like growth factors (IGF-I/IGF-II) 370  
 integrins 285, 287  
   as a therapeutic target 290  
 intercellular adhesion molecule 1 (ICAM1) 287  
 interleukin-1 (IL-1) 275–6, 387–8  
 interleukin-1 receptors (IL-1R) 274–6  
 interleukin-6 (IL-6) 276  
 interleukin-8 (IL-8) 355  
 interleukin-11 (IL-11) 289–90  
 internal ribosome entry site (IRES) 72, 80–1  
 International Cancer Genome Consortium (ICGC) 501  
 intravasation 282–5, 299  
 irinotecan 327, 482  
 isocitrate dehydrogenases (IDH1/IDH2) 300, 334  
 Jagged1 445  
 JNK kinase 224  
 juvenile polyposis 391  
 KAI1 (metastasis suppressor) 291  
 karyotyping 95  
   digital 96–7  
 kidney, renal cell carcinoma 213, 239, 430  
 kinetic models in metabolomics 304  
 KRAS/KRAS 184, 477  
   activating mutations 183, 188, 477–8  
   and response to anti-EGFR therapy 478, 506  
   in colon cancer 188, 379  
   in lung cancer 426–7, 430–3, 435–6  
   in pancreatic cancer (*KRAS2*) 188, 410–12  
   *see also* RAS signaling pathways  
 lactate dehydrogenase (LDH) 300  
 laminin receptors 316  
 LAPTM4B amplification in breast cancer 510  
 large latent complex (LLC) 204  
 latency-associated proteins (LAPs) 204  
 latent TGF $\beta$  binding proteins (LTBPs) 204  
 LATS2 (tumor suppressor) 143  
 lerdelimumab 213  
*let-7* family of miRNAs 137–9, 430–1

- leukemia  
 ALL 26–8, 81, 122, 504  
 AML 145, 418, 444–6, 504  
 CLL 451–2  
 CML 95  
 deletions 139, 451  
 DNA methylation profiles 120  
 eIF4E 80  
 miRNAs 122, 139–40  
 translocations 100  
   in AML/APL 145, 444–5  
   in CML 95  
   MLL locus 445–6
- leukocytes  
 and metastasis 285, 312–13  
 and TGF $\beta$  208–9, 212  
 inflammation 275, 329, 476–7
- Li–Fraumeni syndrome 390, 410, 480
- LIN28* (RNA binding protein) 137
- lineage addiction 436
- lipid synthesis 300
- liquid chromatography 303
- liver cancer  
 metastatic 289, 312  
 primary *see* hepatocellular carcinoma
- LKB1* (*STK11*) 390–1, 396, 433–4
- loss of heterozygosity (LOH)  
 in glioblastoma 323–4, 331  
 in stomach cancer 392
- LOX (lysyl oxidase) 288
- LRP/Lrp (low-density lipoprotein-related protein receptor family) 224, 229
- LRRFIP2 protein (Wnt regulator) 229
- lung cancer 421–37  
 classification 431, 504  
 EGFR 421, 426–8, 432, 437  
 epidemiology 421, 425  
 epigenetics 429–31, 437  
 FGF/FGFR 424, 429  
 genomic studies 24, 26, 425–9  
 histology  
   normal lung 422–3  
   SCLC and NSCLC 424–5  
 KRAS 426–7, 430–3, 435–6  
 metastatic 289, 312, 354  
 miRNA 138, 430–1  
 p53 426  
 PI3K/PTEN/mTOR pathways 277, 433–6  
 prognostic markers 138, 430–1, 484  
 signaling networks in cancer 431–4  
 signaling networks in normal lung development 423–4  
 stem cells in normal lung 422  
 TGF $\beta$  25–7, 424  
 treatment 434–7
- ALK inhibitors (crizotinib) 435, 507
- beta-carotene 459
- drug resistance 81, 436–7
- EGFR inhibitors 435, 484, 505–6
- paclitaxel 175
- lymphoma  
 Bmi1 overexpression 124  
 Burkitt's lymphoma 450–1  
 DLBCL 447–50, 504  
 DNA methylation profiles 120  
 MALT 448  
 therapeutic targets 81–2, 449–50, 452  
 translocations 100, 448
- lysyl oxidase (LOX) 288
- macrophages, tumor-associated (TAM) 275, 285
- MAGED1* (melanoma antigen, family D, 1) 27
- magnetic resonance imaging (MRI) 490
- maintenance genes  
 always expressed in tumors 28–31  
 underexpressed in tumors 25–8
- MALT lymphoma 448
- Mammaprint test 347
- mapatumumab 267
- MAPK (mitogen-activated protein kinase) signaling pathway 173, 186, 195, 379
- inhibitors 190
- mass spectrometry 303  
 AP-MS 230–1
- mate-paired DNA libraries 8, 14–16
- matrix metalloproteases (MMPs) 284–5  
 inhibitors 142, 290–1
- MBD1/MBD2/MBD3/MBD4 (methyl binding domain proteins) 117, 125, 160
- Mcl-1 (anti-apoptotic) 79, 261
- MCM complex/helicase 36–9
- MDM2/MDM2* (p53 antagonist) 171, 196, 331
- medroxy-progesterone acetate (MPA) 291
- medulloblastoma 23–4, 240
- melanoma  
 genes 25, 188  
 metastasis 289, 315  
 staging 473–4  
 treatment 190, 213
- mesenchymal to epithelial transition (MET) 287
- MET/c-Met* (receptor tyrosine kinase) 267, 325–6, 394–5
- meta-analysis of genomic data 501–2
- metabolism 295–305  
 analytical methods in metabolomics 302–4  
 functional PET imaging 490–1  
 glucose 196, 296–9, 302  
 glutamine 300–1  
 IDH1/IDH2 300, 334  
 metabolomics of colon cancer 382  
 miRNA regulation 147  
 mitochondrial 299–300  
 nucleotide synthesis 298, 301, 482–3  
 one carbon pathways 155–7
- metastasis 282–91, 309–10  
 and the vascular system 309–10  
 anatomical considerations 289, 311–12  
 and blood components 285, 287, 311–13, 316–17  
 and endothelial cells 282, 311, 315, 317  
 and pericytes 315–16  
 and the endothelial basement membrane 316  
 angiogenesis 284, 310  
 organ-specific metastasis 289, 310–12
- apoptosis/anoikis 282, 285–6, 288, 299
- basement membrane and 284–5, 316–17
- colonization 282, 287–9
- EMT *see* epithelial to mesenchymal transition
- extravasation 282, 285–7, 289, 311, 315–16
- intravasation 282–5, 299
- miRNAs  
 as inducers 80, 122, 142–3  
 as suppressors 143, 287–8, 364  
 primary site identification 21
- of breast cancer  
 differences from primary tumor 349  
 gene profiles 353  
 miRNAs 142–3  
 to specific organs 289, 312, 354–5
- of colon cancer 312
- of prostate cancer *see* prostate cancer, EMT and metastasis
- organ-specific 287–90, 310–12, 354–5
- primary site identification 20–2
- suppressor genes 143, 288, 291
- TGF $\beta$  and 209, 278, 283–4, 289, 354, 365
- therapeutic targets 290–1, 316–17  
 to bone 287–90, 354, 368
- metelimumab 213
- methionine metabolism 155–7
- methionine synthase (MS) 156–7



## Index

- methyl binding domain proteins (MBD1/2/3/4) 117, 125, 160
- methylation of DNA *see* DNA methylation
- methylation of histones *see* histone methylation
- methylenetetrahydrofolate reductase (MTHFR) 155
- MGMT/MGMT* (O-methylguanine-DNA methyltransferase) 332–3
- microarrays 56–7, 115, 233, 413
- microenvironment of cancer cells 4–5
- micronutrients 155–6
- microRNA (miRNA) 120–2, 134–48, 430
- and epigenetic mechanisms
    - mechanisms' effect on miRNA 120–2, 136, 144–5
    - miRNA's effect on the mechanisms 144
  - and metastasis
    - induction 80, 122, 142–3
    - primary site identification 21
    - suppression 143, 287–8, 364
  - breast cancer 142–3
  - cellular networks targeted by 145–7, 365
  - downregulation in cancer 136–7
  - hematological cancers 122, 139–40, 451
  - let-7* family 137–9, 430–1
  - libraries 175–7
  - lung cancer 138, 430–1
  - miR-1 144
  - miR-10b 142
  - miR-15a/miR-16 139, 367, 451
  - miR-17-92 cluster 139–41, 366–7, 431
  - miR-21 80, 141–2, 431
  - miR-29 144, 147
  - miR-31 143, 288
  - miR-34 177
  - miR-35 176–7
  - miR-101 144
  - miR-124a 122
  - miR-126 143
  - miR-127 122, 145
  - miR-145 370
  - miR-196a2 431
  - miR-200 287, 434
  - miR-205 364
  - miR-335 143
  - miR-373 142, 175
  - miR-520c 142
  - mRNA binding 136
  - oncogenes 139–42, 145, 175–7
  - prostate cancer 139, 364, 366–7, 370
  - synthesis 135–6
  - tumor suppressor genes 137–9, 141, 145, 177
- microsatellite instability (MIN/MSI) 101–2, 380–1, 392–3
- miRview™ 21
- mismatch repair genes
  - MLH1/MSH2 102, 377–8, 389–90, 392
  - MSH6 333
- mitochondria
  - energy metabolism 299–300
  - role in apoptosis 261
- mitosis 93, 105–6
- in cancer cells 93
- MLH1 (mismatch repair) 102, 377–8, 389–90, 392
- MLL (mixed lineage leukemia locus) translocations 445–6
- MMMN cancer progression model 1–5
- MNK kinases 73–4
- mode-of-action network identification 461–2
- modularity of networks 461
- MRI (magnetic resonance imaging) 490
- mRNA
  - binding of miRNA 136
  - structure and translational control 71–2, 79–81
- MSH2 (mismatch repair) 102, 377–8, 389–90, 392
- MSH6/MSH6* (mismatch repair) 333
- MTA3 (Bcl-6 effector) 449–50
- mTOR/mTORC1 (mammalian target of rapamycin) 71, 78, 196, 433–4
- as a therapeutic target 81–2
- MUC-1 (CA 15-3) 487
- MUC-16 (CA-125) 486
- multi-hit hypothesis 108–9
- multi-modular molecular networks (MMMN), overview 1–5
- multiple myeloma 76, 446–7, 504
- mutator hypothesis 101
- MYC/Myc/c-Myc* (transcription factor) 66, 74, 79–80, 235, 277
- and prognosis 479
  - and miRNA 136, 140–1, 366–7
  - in Burkitt's lymphoma 450–1
  - glucose metabolism 297
  - glutamine metabolism 301
- myeloid-derived suppressor cells (MDSC) 278
- MYH* (excision repair gene) 391
- N-cadherin 364
- N-Myc 66
- NADH/NAD<sup>+</sup> 297
- NADPH/NADP<sup>+</sup> 297–9, 301
- nanopore sequencing 12, 126
- NCI60 panel of cancer cell lines 509–10
- nestin 335
- network biology/network medicine 460–3, 502–3
- next-generation sequencing 7–12, 57, 233, 416–18
- and epigenetics 115–16, 118–19, 126
- NF-κB (transcription factor)
  - and AKT 187, 196
  - apoptosis 263–4
  - DLBCL 447–8
  - inflammation 273–6
  - MALT lymphoma 448
  - multiple myeloma 446–7
- NF1/NF1* (neurofibromin 1) 186, 188, 333–4, 432
- NIK1 kinase 447
- 9-1-1/ATR/Chk1 pathway 42–4
- nitrogen metabolism 301
- NK cells 209
- NKX2.1/NKX2.1* (transcription factor) 427, 434, 436
- NME1 (non-metastatic cell 1) 291
- NMR spectroscopy 302–3
- non-Hodgkin's lymphoma
  - c-Myc*-driven apoptosis in Burkitt's lymphoma 450–1
  - DLBCL 447–50, 504
- non-oncogene addiction 443, 446, 452
- see also* oncogene addiction (dependency)
- non-small cell lung carcinoma (NSCLC)
  - ALK inhibitors (crizotinib) 435, 507
  - EGFR inhibitors 435, 484, 505–6
  - paclitaxel 175
  - prognostic markers 138, 430–1, 484
  - PTEN 277
  - subtypes 421, 425
  - see also* lung cancer
- non-steroidal anti-inflammatory drugs (NSAIDs) 236, 398, 459
- Noxa (Bcl-2 protein) 260–1, 263
- NRAS/NRAS* 183–4, 188, 444–5
- see also* RAS signaling pathways
- NSCLC *see* non-small cell lung carcinoma
- nuclear morphometry 475–6
- nucleosome free regions (NFRs) 61–2
- nucleosome structure 117
- nucleotide synthesis 298, 301, 482–3
- nutrition 154
- colon cancer risk 377
  - nutritional epigenomics 119, 155–64
  - nutritional genomics 154–6
  - stomach cancer risk 387

- olaparib 355  
 oncofetal biomarkers 474–5, 485–8  
 oncogene addiction (dependency)  
 435–6  
 loss 437  
*see also* non-oncogene addiction  
 oncogenes (gain-of-function genes) 3,  
 103  
 activation 45  
 inflammation and 277  
 miRNAs 139–42, 145, 175–7  
 prognostic 477–82  
 techniques for identification 174–7  
 transformation models 170–4  
*see also individual genes*  
 Oncomine database 415, 469, 502  
 oncomirs *see* microRNA (miRNA)  
 Oncotype Dx test 347  
 online resources *see* databases  
 ORC (origin recognition complex)  
 36, 39  
 ORF (open reading frame) libraries  
 175  
 origin licensing 35–40  
 deregulation (leading to re-  
 replication) 40–6  
 insufficient 46–50  
 osteoclasts 290  
 ovarian cancer 25–6, 486, 504  
 overdiagnosis 459–60, 465  
 oxidative stress 157, 160, 298–9, 301
- p14<sup>ARF</sup>* (*CDKN2A*) 172, 330–1, 412, 450  
*p15<sup>INK4B</sup>* (*CDKN2B*) 208, 332  
*p16<sup>INK4A</sup>* (*CDKN2A*) 172, 331, 429  
 in Burkitt's lymphoma 450  
 in esophageal carcinoma 395  
 in pancreatic cancer 410, 412  
*p18<sup>INK4C</sup>* 332  
*p21* (*CDKN1A*) 171  
*p53* (transcription factor)  
 and prognosis 331, 481  
 angiogenesis 171  
 apoptosis 172, 196, 263, 450–1  
 DNA repair/replication 41, 171  
 glucose metabolism and 297  
 in cancer 65–6, 171–2, 479–81  
 breast 66, 481  
 colon 380  
 glioblastoma 327, 330–1  
 lung 426  
 pancreas 410, 412  
 stomach 394, 397  
 Li–Fraumeni syndrome 390, 480  
 oxidative stress 299  
 regulation of *p53* 172, 197  
 senescence 171–2  
*p120GAP* (GTPase-activating protein)  
 186
- paclitaxel 175, 478  
 paired-end mapping 15–16, 97, 101  
 PAM50 test 347  
 pancreatic cancer 409–18  
 bioinformatics methods 415–16  
*BRCA2* 412  
*CDKN2A/p16<sup>INK4A</sup>* 410, 412  
 genomic studies 412–15  
*KRAS2* 188, 410–12  
 MRI imaging 490  
*p53* 410, 412  
 prognostic markers 487  
 progression model 409–10  
*SMAD4/DPC4* (and TGF $\beta$ ) 210–12,  
 410–12  
 treatment 82, 409  
 Pancreatic Expression database 415  
 panitumumab (Vectibix®) 478, 506  
 papillary carcinoma of the thyroid  
 277  
 PARAs (pro-apoptotic receptor  
 agonists) 266–7  
 PARP inhibitors 355  
 passenger mutations 3, 15, 97  
 Pasteur, Louis 295  
 Pathwork Diagnostics tissue-of-origin  
 test 21  
 pattern recognition strategies 240  
*PBRM1* (SWI/SNF component) 430  
 PCNA (proliferating cell nuclear  
 antigen) 39–40  
 PCR *see* polymerase chain reaction  
 PDA (pancreatic ductal  
 adenocarcinoma)  
*see* pancreatic cancer  
*Pdcd4* (tumor suppressor) 77–8, 80  
 PDGF (platelet-derived growth factor)  
 314–15, 327  
 PDK (pyruvate dehydrogenase kinase)  
 300  
 PDK1 (3-phosphoinositide-dependent  
 protein kinase 1) 187, 193–4  
 pemetrexed 483  
 pentose phosphate pathway (PPP)  
 298–9  
 pericytes 315–16  
 perifosine 190  
 PERK (protein kinase) 78  
 personalized medicine 505–7  
 clinical trials 458–9, 506–7  
 in breast cancer  
 chemoresistance 355, 510  
 trastuzumab 199, 346, 355, 506  
 in lung cancer 436, 459, 505–6  
 use of cancer cell lines in preclinical  
 studies 507–11  
 PET (positron emission tomography)  
 490–1  
 Peutz–Jeghers syndrome 390–1
- pharmacogenomics 499–513  
 in breast cancer  
 chemoresistance 355, 510  
 trastuzumab 199, 346, 355, 506  
 clinical trials 458–9, 506–7  
 data generation and management  
 500–3, 511–12  
 in lung cancer 436, 459, 505–6  
 molecular subtype classification  
 503–5  
 use of cancer cell lines in pre-  
 clinical studies 507–11  
 4-phenylbutyric 145  
 phosphate and tensin homolog  
*see* PTEN  
 phosphatidylinositol ether lipid  
 analogues (PIAs) 190  
 phosphatidylinositol-3,4,5-  
 triphosphate (PIP3) 187,  
 193–4, 433  
 phosphoflow cytometry 446  
 phosphofructokinase 1 (PFK1) 299  
 3-phosphoinositide-dependent protein  
 kinase 1 (PDK1) 187, 193–4  
 phospholipase C $\epsilon$  (PLC $\epsilon$ ) 187  
 phytochemicals (anticancer) 158–60  
 PI3K signaling pathway  
 (phosphatidylinositol 3-  
 kinase) 193–200  
 and AKT 193–6, 329  
 and glucose metabolism 297  
 and PTEN 189, 193, 328  
 AKT-independent pathways  
 196–8  
 and radioresistance 325  
 and RAS 173, 186–7, 194–5, 198–9,  
 329, 435–6  
 as a therapeutic target 81, 435–6  
 in cancer 198–200, 382, 479  
 breast 199, 479  
 colon 379–80  
 glioblastoma 81, 325–6, 328–9,  
 333–4  
 lung 433–6  
 stomach 394  
 mTORC1 regulated by 78, 196  
 overview 193–4, 328, 433, 479  
 PIP3 (phosphatidylinositol-3,4,5-  
 triphosphate) 187, 193–4, 433  
 PKB (protein kinase B) *see* AKT  
 signaling pathway  
 PKC (protein kinase C) family 187,  
 190  
 PKR (protein kinase R) 75–6, 78  
 platelet-derived growth factor (PDGF)  
 314–15, 327  
 platelets, tumor-associated 287, 312  
 PML/RAR $\alpha$  translocation and fusion  
 444–5

## Index

- PODXL (podocalyxin-like) 287  
 Pol II (RNA polymerase II) 59–60  
   stalling 64  
 polo-like kinase 4 (Plk4) 108  
 polycomb repressive complex 123–4,  
   144, 430  
 polymerase chain reaction (PCR)  
   DDRT-PCR 232–3  
   emulsion PCR 8  
   RT-PCR in tissue-of-origin  
     identification 22  
   solid phase PCR 8  
 position weight matrices (PWMs)  
   243  
 positron emission tomography (PET)  
   490–1  
 post-translational modification  
   glycosylation 262, 301, 466–7  
   in apoptotic pathways 261–2, 265  
   RAS 184  
   *see also* histone modification  
 PP2A (tumor suppressor) 172–3  
 PPI (protein–protein interaction)  
   networks 146, 241–3  
 pre-initiation complex (PIC) 64  
 pre-replication complex 35–6  
 predictive biomarkers 458  
   *see also* therapeutic response  
   markers  
 pro-apoptotic receptor agonists  
   (PARAs) 266–7  
 prognosis 473–91  
   biomarkers 458, 474  
   cell surface receptors 483–5  
   DCP 483  
   EMT markers 477  
   imaging 488–91  
   oncofetal serum markers 474–5,  
     485–8  
   oncogenes 477–82  
   thymidylate synthase 482–3  
   tumor grade 475–6  
   tumor infiltration by lymphocytes  
     476–7  
   tumor stage 473–4, 476  
   in breast cancer 347–8, 461, 479,  
     481, 484, 503  
   in CLL 451–2  
   in colon cancer 482–3, 486–7  
   in glioblastoma 331  
   in HCC 483–4, 488  
   in lung cancer 138, 430–1, 484  
   in pancreatic cancer 487  
   in stomach cancer 397–8, 484  
   patient factors 474  
     *see also* therapeutic response  
     markers  
 prolyl-hydroxylases (PHD) 299–300  
 prominin (CD133) 334–5  
 prostate cancer 361–71  
   EMT and metastasis  
   cadherins 364  
   EGFR 370  
   experimental models 363–4  
   FGF/FGFR 363–4, 369  
   Hedgehog signaling 366–7  
   IGF 370  
   TGF $\beta$  368–9  
   to bone 290, 368  
   transcription factors 363–6  
   Wnt signaling 367–8  
   ERG/ETV1/TMPRSS2 gene fusions  
     367, 469–70  
   miRNAs 139, 364, 366–7, 370  
   molecular subtypes 504  
   network analysis 461–2  
   prostate gland development 361  
 proteasome 443  
   inhibitors (bortezomib) 76, 267, 447  
 protein kinase B (PKB) *see* AKT  
   signaling pathway  
 protein kinase C (PKC) family 187,  
   190  
 protein kinase R (PKR) 75–6, 78  
 protein synthesis, regulation 70–2  
   as a therapeutic target 81–2  
   eIFs 70–1, 73–7  
   mRNA structure 71–2, 79–81  
   signaling pathways 77–80  
 protein tyrosine phosphatases (PTPs)  
   381–2, 394  
   *see also* PTEN  
 protein–protein interaction (PPI)  
   networks 146, 241–3  
 proteomics 230–2  
   and Wnt signaling pathways 231–2  
   colon cancer 382  
   stomach cancer 397–8  
 prothrombin (DCP) 483  
 PRSS11 (protease, serine, 11) 25  
 PTEN (phosphate and tensin  
   homolog)  
   and miRNAs 140, 142  
   and p53 197  
   as a therapeutic target 81  
   in cancer 198, 479  
   breast 199, 479  
   colon 380  
   glioblastoma 326, 328–9, 333–4  
   lung 277  
   PI3K pathway 189, 193, 328  
   AKT-independent pathways  
     196–8  
   PTPs (protein tyrosine phosphatases)  
     381–2, 394  
   *see also* PTEN  
 pulmonary neuroendocrine (PNE)  
   cells 422–5  
 PUMA (Bcl-2 protein) 260–1, 263–5  
 pyrosequencing 11, 233  
 pyruvate dehydrogenase kinase (PDK)  
   300  
 pyruvate dehydrogenase (PDH) 300  
 pyruvate kinase (PKM1/PKM2) 297–8  
 pyruvate metabolism 296–7, 300  
  
 quantitative nuclear grade (QNG)  
   475–6  
  
 RAC (RHO GTPase) 173, 187  
 racial differences in breast cancer 345  
 radioresistance 325–6  
 RAF (RAS effector) 173, 186, 195, 433  
   BRAF 188, 190, 379, 478–9  
 RAL-GDS (RAS effector) 187  
 RANKL (receptor activator of NF- $\kappa$ B  
   ligand) 287–8, 290, 368  
 rapamycin 81–2, 175  
 RAS signaling pathways 183–91  
   downstream pathways 173–4, 186–7  
   phospholipase C $\epsilon$  187  
   PI3K 173, 186–7, 194–5, 198–9,  
     329  
   RAF/BRAF 173, 186, 188, 190,  
     195, 379, 433, 478–9  
   RAL-GDS 187  
   HRAS/HRAS 173, 183–4  
   in cancer 173–4, 183, 188–9  
   breast 185  
   colon 188, 379  
   lung 426–7, 430–3, 435–6  
   metastasis 286, 288  
   pancreas 188, 410–12  
   inflammation 277  
   KRAS/KRAS *see* KRAS/KRAS  
   NRAS/NRAS 183–4, 188, 444–5  
   post-translational modification 184  
   prognostic significance of KRAS  
     mutations 477–8, 506  
   regulation of RAS 173, 184–6,  
     432–3  
   miRNAs (*let-7*) 138, 430–1  
   structure of RAS 183–4  
   therapeutic targets 173, 189–91,  
     329, 435–6  
 RB/Rb (retinoblastoma protein)  
   signaling pathway 37, 49, 172,  
   186, 331–2  
 reactive oxygen species (ROS) 298–9  
   *see also* oxidative stress  
 real-time sequencing 11  
 receptor tyrosine kinases (RTKs)  
   *see individual proteins*  
 renal cell carcinoma 213, 239, 430  
 repertaxin 355  
 re-replication of DNA 40–6  
   prevention 38–50

- resistance  
 to chemotherapy *see* drug resistance  
 to radiotherapy 325–6
- RET/PTC translocation and fusion 277
- retinoblastoma 108
- retinoblastoma protein (RB/Rb)  
 signaling pathway 37, 49, 172, 186, 331–2
- Rheb (GTPase) 81–2, 175
- RHO GTPases (RAC) 173, 187
- ribavirin 82
- ribose-5-phosphate 298
- RNA  
 double-stranded 326  
 microRNA *see* microRNA (miRNA)  
 mRNA structure 71–2, 79–81
- RNA editing (A to I) 145
- RNA helicase (eIF4A) 76–7, 80
- RNA interference (RNAi) 174–5, 228  
 eIF4E 82  
 Wnt signaling pathways 228–9  
*see also* microRNA (miRNA)
- RNA polymerase II (Pol II) 59–60  
 stalling 64
- RNase III (Dicer) 136–7
- RNase III (Drosha) 135–6
- robust multichip average (RMA)  
 analysis 240
- ROC (receiver operating characteristic) curves 458
- rolling circle amplification (RCA) 8
- RT-PCR (reverse transcription polymerase chain reaction) 22  
 DDRT-PCR 232–3
- rucaparib 355
- RUNX3 (tumor suppressor) 395
- S6 kinase (S6K) 80, 187
- salinomycin 355
- SAM (S-adenosyl methionine) 157
- SARA (Smad anchor for receptor activation) 205
- sarcomas 100
- sarcosine 470
- SCF<sup>SKP2</sup> (CRL1<sup>SKP2</sup>) 39, 41
- SCLC (small-cell lung carcinoma) 24,  
 424–5, 429, 431, 434
- screening biomarkers 458  
 colon cancer 378  
 over- and underdiagnosis 459–60,  
 465  
 threshold adjustment 470
- SDF1 (stromal derived factor 1) 289
- seasonal effects on epigenetics 161–2
- secreted frizzled-related proteins 3 and  
 4 (sFRP3/sFRP4) 367–8
- selectins 287, 312–13, 315  
 as therapeutic targets 317
- senescence of cells 171–2
- sequencing *see* genome sequencing
- sequencing by DNA observation 12
- sequencing by ligation (SBL) 11–12
- sequencing-by-synthesis (SBS) 10–11
- serine 298
- serum biomarkers 474–5, 485–8
- sex steroids *see* steroid hormones
- sFRP3/sFRP4 367–8
- single molecule sequencing 9, 12
- single nucleotide polymorphism/  
 variation (SNP/SNV) 13–15,  
 97
- SLUG (transcription factor) 365
- SMAC protein 259, 266
- Smad proteins 204–6, 210, 368  
 in colon cancer 210–12, 380  
 in pancreatic cancer (Smad4)  
 210–12, 410–12  
 in prostate cancer (Smad3) 368  
 in stomach cancer (Smad4) 391, 396
- small-cell lung carcinoma (SCLC) 24,  
 424–5, 429, 431, 434
- smoking  
 lung cancer 421, 425  
 stomach cancer 388
- Smurf1/Smurf2 (E3-ubiquitin ligases)  
 205
- SNAIL (transcription factor) 363–5
- SNP/SNV (single nucleotide  
 polymorphism/variation)  
 13–15, 97
- sodium bisulfite technique 114, 126
- solid phase PCR 8
- sorafenib 239
- SOX2 (stem cell transcription factor)  
 429, 434
- spectral karyotyping (SKY) 96
- SPEED database 243
- spindle assembly checkpoint (SAC)  
 105–6
- Sprouty 1/Sprouty 2 (SPRY1/SPRY2)  
 142, 424
- squamous cell lung carcinoma 24
- ST6GALNAC5 289
- staging of cancers 476  
 colon 378  
 melanoma 473–4  
 stomach 387 *see also* classification  
 of cancers
- STAT3 (transcription factor) 275, 329
- steroid hormones  
 in breast cancer 185, 345, 351  
 in prostate cancer 276, 361
- STK11 (LKB1, protein kinase) 390–1,  
 396, 433–4
- STK15 (protein kinase) 394
- stomach cancer 386–98  
 apoptosis 395–6
- classification and staging 387  
 diffuse-type 387, 389  
 E-cadherin 389, 393–4  
 epidemiology 386–8  
 epigenetic modifications 392, 395  
 familial forms 388–91  
 FHIT 394  
 genome instability 391–3  
 genotypes associated with 387–8  
 growth factors 395–6  
 intestinal-type 387, 389–92, 396  
 MET 394–5  
 p53 394, 397  
 PI3K pathway 394  
 prognostic markers 397–8, 484  
 PTPs 394  
 somatic alterations (various) 396–7  
 TFF1 393  
 TGF $\beta$  signaling 393  
 treatment  
 chemosensitivity markers 398  
 targets 398  
 Wnt signaling 396
- stroma  
 and FGF10 in prostate cancer 369  
 and HGF in stomach cancer 394–5  
 and TGF $\beta$  209 *see also* extracellular  
 matrix
- succinate dehydrogenase (SDH)  
 299–300
- suicide genes 82
- sulindac 236
- surrogate endpoint biomarkers 458
- synthetic lethality 355, 436
- systems biology, definition 464
- T cells  
 and STAT 329  
 and TGF $\beta$  208–9, 212  
 tumor infiltration and prognosis  
 476–7  
*see also* hematological cancers
- TAM (tumor associated macrophages)  
 275, 285
- tamoxifen 175, 346
- tanshinone-I 160
- targeted resequencing 16–17
- TATA box 60
- TCA (tricarboxylic acid) cycle  
 299–301
- TCF7L2 (Wnt regulator) 174, 226,  
 229
- telomeres/telomerase 106–8, 170–1  
 in stomach cancer 397
- temozolomide 332–3
- TFF1 (trefoil peptide) 393
- TFIIB (transcription factor) 65
- TGCA (The Cancer Genome Atlas) 4,  
 177, 501

## Index

- TGF $\beta$  signaling pathway(s)  
 (transforming growth factor  $\beta$ )  
 204–14  
 and chemokines 278  
 and metastasis 209, 278, 283–4, 289,  
 354, 365  
 and miRNAs 147, 365  
 and Smad proteins 204–6, 210, 368  
 as a therapeutic target 212–14, 290  
 in cancer 209–12  
   breast 212, 353  
   colon 210–12, 380  
   glioblastoma 327  
   lung 25–7, 424  
   pancreas 210–12, 410–12  
   prostate 368–9  
   stomach 393  
 in embryonic development 207  
 in immunosuppression 208–9, 212  
 in the cell cycle 207–8  
 overview 205–6, 368  
 receptors 205  
 synthesis and activation of TGF $\beta$   
 204
- therapeutic response markers  
 474–5  
 8q22 amplification 510  
 BRAF mutations 478–9  
 EGFR mutations 484, 505–6  
 ERCC1 mutations 482  
 HER2 506  
 in stomach cancer 398  
 KRAS mutations 478, 506  
 MYC amplification 479  
 PI3KCA/PTEN mutations 479  
 serum markers 486–7  
 thymidylate synthase 483
- therapeutic targets  
 apoptosis 265–7  
 EGFR *see* epidermal growth factor  
 receptor (EGFR), as a  
 therapeutic target  
 eIF4E 82  
 epigenetic alterations 145, 437  
 in breast cancer 355  
 in glioblastoma 326–9, 335–6  
 in hematological cancers 81–2, 447,  
 449–50, 452  
 in lung cancer 435–6  
 in stomach cancer 398  
 metastasis 290–1, 316–17  
 mTOR 81–2  
 RAS/KRAS signaling 173, 189–91,  
 329, 435–6  
 synthetic lethality 355, 436  
 TGF $\beta$  signaling 212–14, 290  
 translational control 81–2  
 vascular system 290, 316–17, 327  
 VEGF 290, 316, 327
- Wnt signaling 227–8, 235–9  
*see also* pharmacogenomics
- threshold analysis 240
- thrombospondin-1 (TSP1) 140, 171
- thymidylate synthase (TS) 482–3
- thyroid cancer 277
- TIGAR (TP53-induced glycolysis and  
 apoptosis regulator) 299
- TIR8 (Toll-interleukin receptor 8)  
 274–6
- TNF *see* tumor necrosis factor (TNF)  
 superfamily
- Tnik kinase 231
- TNM staging system 476
- TOPFlash method 228–9
- TP53  
 in colon cancer 380  
 in glioblastoma 327, 330–1  
 in lung cancer 426  
 in pancreatic cancer 410, 412  
 in stomach cancer 394  
*see also* p53 (transcription factor)
- TRAF2/TRAF3 (TNF receptor-  
 associated factors) 447
- TRAIL receptors (TNF-related  
 apoptosis-inducing ligand, Dr4  
 and DR5) 262, 266–7, 396
- transcription factors *see individual  
 factors*
- transcription, regulation 58–65, 145–6  
 analytical techniques 56–8  
 in cancer 65–7
- transcription start sites (TSSs) 59–62
- transcriptomics  
 high-throughput sequencing 16, 57  
*see also* gene expression profiles
- transforming growth factor  $\beta$   
*see* TGF $\beta$  signaling pathway(s)
- transketolases/transaldolases (TK/TA)  
 298
- translation, regulation 70–2  
 as a therapeutic target 81–2  
 eIFs 70–1, 73–7  
 mRNA structure 71–2, 79–81  
 signaling pathways 77–80
- translational research in drug  
 discovery 500, 510–11  
 implications for clinical trials  
 506–7  
 use of cancer cell lines in pre-  
 clinical studies 507–11
- translocations 100  
 in leukemias  
   AML/APL 145, 444–5  
   CML 95  
   MLL locus 445–6  
 in lung cancer 427–9, 436, 507  
 in MALT lymphoma 448  
 in thyroid cancer 277
- trastuzumab (Herceptin®) 190, 199,  
 346, 355, 506
- TTF-1 *see* NKX2.1/NKX2.1
- tumor associated macrophages (TAM)  
 275, 285
- tumor necrosis factor (TNF)  
 superfamily  
 apoptosis 259, 262  
 inflammation 275
- tumor suppressor genes (loss-of-  
 function genes) 3, 25–8, 103  
 epigenetic gene silencing 119–20,  
 124, 160, 381  
 inflammation and 277–8  
 miRNAs 137–9, 141, 145, 177  
 techniques for identification 174–7  
*see also individual genes*
- TWIST (transcription factor) 142, 365
- tyrosine kinase inhibitors 190, 267  
*see also* erlotinib; gefitinib; imatinib
- unfolded protein response (UPR) 78
- vaccines  
 targeting EFGR 326  
 targeting TGF $\beta$  213
- validation of biomarkers 458, 467–8
- vascular endothelial growth factor  
 (VEGF)  
 and Smad4 210–12  
 angiogenesis 171, 196, 284, 288,  
 314  
 as a therapeutic target 290, 316, 327  
 family members 314  
 in glioblastoma 326–7  
 in stomach cancer 396  
 metastasis 284, 288
- vascular system 309–17  
 angiogenesis *see* angiogenesis  
 metastasis  
   anatomical considerations 289,  
   311–12  
   and blood components 285, 287,  
   311–13, 316–17  
   and endothelial cells 311, 315, 317  
   and pericytes 315–16  
   and the endothelial basement  
   membrane 316  
   angiogenesis 284, 310  
   intravasation 282–5, 299  
   organ-specific 289, 310–12  
   therapeutic targets 290, 316–17, 327  
   *see also* hematological cancers
- VCAM-1 (vascular cell adhesion  
 molecule 1) 287, 315
- VEGF *see* vascular endothelial growth  
 factor
- veliparib 355
- versican 275

- vimentin 363, 368  
 viral oncolytic therapies 82, 190  
 visualization tools 416  
 vitamins 155–6  
 Von Hanseemann, D. 93
- Warburg, Otto 295  
 water, contaminated 161  
 white blood cells  
   and metastasis 285, 312–13  
   and TGF $\beta$  208–9, 212  
   inflammation 275, 329, 476–7  
     *see also* hematological cancers  
 whole-genome sequencing 17, 412–18  
   *see also* genome sequencing  
 Wnt signaling pathway 222–47  
   and EMT/metastasis 367–8
- in cancer 225–8  
   colon 177, 226, 245, 379  
   prostate 367–8  
   stomach 396  
 canonical ( $\beta$ -catenin) pathway 174,  
   223–4, 245–6, 367, 370  
   in cancer 226–7, 245, 367–8, 379,  
   396  
   proteomics 231–2  
   RNAi 228–9  
   target genes 233–5  
 computer models 244–6  
 data analysis methods 240–4  
 extracellular modulators 224–5  
 networks  
   methods of identification 228–32  
   pathway interactions 225, 241
- protein–protein interaction  
   analysis 241–3  
 non-canonical pathways 224, 227  
 target gene identification 232–5, 243  
 therapeutic targets 227–8, 235–9  
*Xenopus* bioassay 222–3  
 WTX protein (Wilms' tumor on the  
 X) 231
- yeast two-hybrid (Y2H) technique  
 231–2  
 YWHAZ amplification in breast  
 cancer 510
- ZAP-70 (tyrosine kinase) 451  
 ZEB1/ZEB2 (transcription factors)  
 287, 365–6, 434